CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury.
Lodka D, Zschummel M, Bunse M, Rousselle A, Sonnemann J, Kettritz R, Höpken UE, Schreiber A.
Ann Rheum Dis. 2024 Mar 12;83(4):499-507. doi: 10.1136/ard-2023-224875.
Crescentic glomerulonephritis in children.
Mayer U, Schmitz J, Bräsen JH, Pape L.
Pediatr Nephrol. 2020 May;35(5):829-842. doi: 10.1007/s00467-019-04436-y. Epub 2020 Feb 12.
Drug-induced glomerulopathies.
Izzedine H, Launay-Vacher V, Bourry E, Brocheriou I, Karie S, Deray G.
Expert Opin Drug Saf. 2006 Jan;5(1):95-106. doi: 10.1517/14740338.5.1.95.
[Crescentic glomerulonephritis].
Ueno M, Arakawa M.
Nihon Rinsho. 1994 Aug;52(8):2082-8.
Crescentic lupus glomerulonephritis.
Yeung CK, Wong KL, Wong WS, Ng MT, Chan KW, Ng WL.
Clin Nephrol. 1984 May;21(5):251-8.
Massive hematuria with rashes: Type II crescentic glomerulonephritis.
Lin Z, Chen C, Xu Y.
Am J Med Sci. 2024 Aug;368(2):e11-e12. doi: 10.1016/j.amjms.2023.11.015. Epub 2023 Nov 22.
Mesangiocapillary glomerulonephritis.
D'Amico G, Ferrario F.
J Am Soc Nephrol. 1992 Apr;2(10 Suppl):S159-66. doi: 10.1681/ASN.V210s159.
Rapidly progressive crescentic glomerulonephritis: Early treatment is a must.
Moroni G, Ponticelli C.
Autoimmun Rev. 2014 Jul;13(7):723-9. doi: 10.1016/j.autrev.2014.02.007. Epub 2014 Mar 19.
High-frequency plasma exchange therapy for immunocompromised, type I crescentic glomerulonephritis complicated with IgA nephropathy: A case report and literature review.
Chen H, Jin J, Cheng MJ, He L, Zhou W, Guo L, Niu ZZ, Liang XN, Zhu RF, Bai Y, Xu JS.
Medicine (Baltimore). 2023 Jan 20;102(3):e32698. doi: 10.1097/MD.0000000000032698.
C3 glomerulonephritis with a severe crescentic phenotype.
Ravindran A, Fervenza FC, Smith RJH, Sethi S.
Pediatr Nephrol. 2017 Sep;32(9):1625-1633. doi: 10.1007/s00467-017-3702-8. Epub 2017 Jun 7.
